why choose us

First received: March 13, 2023

Clinical Trial: Epcoritamab and Rituximab for First-line Follicular Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Follicular Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Study of Epcoritamab and Rituximab for First-line Treatment of Follicular Lymphoma

Brief Summary: The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma.The names of the study drugs involved in this study are:Rituximab (a type of monoclonal antibody therapy)Epcoritamab (a T-cell bispecific antibody)

Read more